H
Health Initiatives Research, PLLC | Fayetteville, AR
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Gantenerumab
Crenezumab
Donanemab
Aducanumab
LY3002813
AVP-786
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 7 total trials
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...
Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...
Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Aducanumab
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...
Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786
Trial sponsors
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems